Welcome to Quantum Biospace,
the Science Park in Belgium
dedicated to Techbio
Welcome to Quantum Biospace, the Science Park in Belgium dedicated to Techbio
We offer Life Sciences and Technology companies the ideal ecosystem to transform drug discovery, development and manufacturing using data-driven approaches
Welcome to our state-of-the-art TechBio science park, strategically located next to Brussels, the biopharmaceutical decision-making heart of Europe. Our unique location places us at the crossroads of three BioRegions: Flanders, Brussels, and Wallonia.
Our science park is specially designed to cater to a wide range of needs, including R&D, manufacturing, and HQ facilities. It’s an ideal place to tap into a large local talent pool of biotech & ICT experts and STEM graduates.
Change the game for patients across the planet
Our mission is to accelerate the AI-powered paradigm shift in the biopharmaceutical industry through a combination of:
State-of-the-art
REAL ESTATE
facilities
State-of-the-art REAL ESTATE facilities
A unique
VENTURE BUILDER
studio
A unique VENTURE BUILDER studio
A world-class
SCIENCE & TECHNOLOGY
community
A world-class SCIENCE & TECHNOLOGY community
By merging together place, talent and funding, Quantum Biospace will actively foster the growth of new TechBio companies.
THE TECHBIO
REVOLUTION
Biopharmaceutical R&D is becoming increasingly slower and more expensive. The power to change this paradigm lies in TechBio, at the interface where life sciences and AI meet.
TechBio is the DNA of Quantum Biospace
We believe the future of drug discovery lies in tech-enabled and AI-first biology.
The timing is right
Recent progress in Big Data in human biology, Machine Learning and High-performance Computing prepared the ground for AI-enabled groundbreaking ways of discovering, developing, and manufacturing drugs.
Quantum Biospace is on a mission
To accelerate TechBio as a disruptive transformation that is poised to enable a quantum leap in drug discovery efficiency. By allowing omics-based drug discovery, AI is making it possible for the first time to use humans as a model for humans.
Quantum Biospace offers 70.000 sqm of scientific facilities
- State-of-the art HQ office spaces
- Specialised dry labs, wet labs, chemistry labs, biosafety labs and clean rooms to facilitate research
- Tailor-made tech and bio-manufacturing infrastructure
- Logistics solutions in support of your commercialisation
- Premium business amenities, refined dining establishment, boutique-style hotel, and dedicated team-building facilities
Quantum Biospace is designed to foster your innovation through interconnective design, collaborative community-services, flexible premises, and much more.
R&D
25 000
sqm
Manufacturing
32 000
sqm
Offices & showrooms
8 000
sqm
Hotel & food
5 500
sqm
Parking places
963
Bike parking places
400
A park that breaths sustainability
Aiming at a BREEAM green building certification
Powered by solar panels and geothermal energy to decrease carbon emissions
Provide green mobility through car and bike sharing, e-car charging stations
Stimulate an active lifestyle, 2 km of bike & walk-lanes in the park and a Golf course next door
For additional information about the facilities in our science park, please download our brochure.
Belgium is big in biopharma
Belgium is big in biopharma and punching far beyond its weight when it comes to the biopharmaceutical industry. Prominent companies such as Janssen Pharmaceuticals, GSK Vaccines, UCB, and Argenx were born here and recognize Belgium as key to their success.
Belgium is at the forefront of biotech innovation
- Channels € 5 billion annually into research and development
- 2nd EU country in Biopharmaceutical manufacturing with € 43 billion annual turnover
- 10 universities featuring leading biotechnology and computer research departments
- 2nd EU country in terms of clinical trials per capital
- A thriving TechBio hub, supported by 42.000 biotech professionals, 120.000 ICT experts, and an annual influx of 22.000 STEM graduates.
PREMIUM LOCATION
In Wavre-Nord, Walloon Brabant, gathering > 25% of the BioTech talent pool
Universities, Research centers and Academic Hospitals
- UCLouvain
- KULeuven
- VUB
- ULB
- CU Saint-Luc
- UZ Brussels
- UZ Leuven
- HUB
- IMEC
- WELRI
- Trusted AI Labs
Biopharmaceutical Industry and related institutions
- GSK
- UCB
- IBA
- European Commission
- FAMHP
- Essenscia
- EFPIA
- AI4Belgium
- Euronext
- SFPI-FPIM
A UNIQUE AND DEDICATED START-UP STUDIO
AI is changing the game, not only in drug discovery but also in biotech entrepreneurship. AI-native biotechs will generate an AI-powered drug development transformation.
That is the reason why we are setting up a unique and dedicated venture studio based on a mixed team of drug discovery and AI experts, an Artificial Intelligence Drug Discovery engine and a seed venture capital fund.
A startup
factory
Unlike traditional incubators or accelerators, Quantum BioVenture creates and nurtures its very own startup concepts with resident researchers and entrepreneurs.
Acting as a true start-up factory using AI from target discovery to preclinical development, Quantum BioVenture brings to the world breakthrough AI-native TechBio companies that will change the game for patients worldwide.
Our partners
About us
Quantum Biospace originates from the collaboration between:
- BVI.EU as a pioneering Belgian industrial real estate developer
- The city of Wavre, host of the world's largest vaccine production site
The science park aims to provide premium real estate facilities and capitalise on the synergy of local life sciences and computer science talents to actively support the upcoming TechBio industry.
Quantum BioSpace
is led by
Quantum BioSpace's leadership includes Geoffroy Dumonceau, Chief Development Officer at BVI.EU, a seasoned real estate developer and Florence Bosco, Head of Biotech Business Development at BVI.EU, a specialist in the development of Life Sciences parks and highly skilled in global biopharma innovation.
Geoffroy Dumonceau
Geoffroy Dumonceau is a seasoned real estate professional with over 20 years of experience. In his current role as Chief Development Officer and a board member at BVI.EU, he spearheads the development and management of business parks tailored to the needs of both SMEs and large national and international corporations.
Throughout his career, Geoffroy has showcased his proficiency in navigating the complexities of the real estate industry and delivering successful outcomes, including in previous roles such as Projects Director at Wilhelm & Co promoting and managing various mixed-use real estate projects, and as Development Manager at Foruminvest Belgium.
In addition, Geoffroy has a background in political advisory, having served in the capacity of a Political Advisor to the Government of the Brussels Capital Region. This unique combination of real estate acumen and political insight sets Geoffroy Dumonceau apart as a well-rounded professional in the field.
Florence Bosco
Fascinated by what creates an affinity between atoms to form molecules and between people to form successful projects, Florence Bosco studied chemical process engineering and consequently joined the biopharmaceutical industry where she has been successfully leading highly innovative projects for more than two decades.
Florence currently holds the position of Head of Biotech Business Development at BVI.EU for QUANTUM BIOSPACE and has navigated roles ranging from R&D engineer to product development manager and innovation project leader, to leadership roles including serving as CEO of Brussels South Charleroi BioPark and heading a biotech startup named Akina Pharmaceuticals. Throughout her professional journey, Florence has excelled in capturing global scientific and industrial trends, and strategically applying them to the local economy.
She is recognized for coordinating extensive collaborative innovation projects in the biopharma and healthcare sector. Backed by her Executive Certificate in Genetics and Genomics from Stanford University, an Executive Certificate in AI for Pharma and Biotech from MIT, and a Certificate in Inspirational Leadership from IMD, Florence regularly serves as a spokesperson in her expertise areas including biotech innovation, AI-first biology and drug development, clinical trial operations and venture capital & start-ups creation.
Her recent publication, a white paper co-authored with Professor Benoît Macq, titled 'How AI is changing the game in drug discovery and entrepreneurship,' reflects her commitment to advancing the field and sharing insights at the intersection of technology and biopharmaceuticals.
LATEST NEWS
& PUBLICATIONS
LATEST NEWS & PUBLICATIONS
Connect
with us